Recursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. reduced its position in Recursion Pharmaceuticals by 5.1%, now owning approximately 8.03% of the company, valued at $170.8 million.
• Research analysts have given the stock an average rating of "Hold" with a price target of $7.00, although Needham & Company has a higher target of $8.00.
• Recursion Pharmaceuticals reported a loss per share of ($0.41) in its latest earnings, missing estimates, but saw a revenue increase of 33.3% year-over-year to $19.1 million.

Vanguard Group Inc. lessened its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,287,977 shares of the company's stock after selling 1,722,017 shares during the period. Vanguard Group Inc. owned about 8.03% of Recursion Pharmaceuticals worth $170,803,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Man Group plc bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $479,000. Invesco Ltd. raised its holdings in shares of Recursion Pharmaceuticals by 54.6% during the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company's stock valued at $1,207,000 after buying an additional 63,068 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of Recursion Pharmaceuticals by 30.7% during the fourth quarter. California State Teachers Retirement System now owns 231,535 shares of the company's stock valued at $1,565,000 after buying an additional 54,449 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Recursion Pharmaceuticals by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company's stock valued at $4,566,000 after buying an additional 12,588 shares during the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $67,000. 89.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RXRX. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective for the company. Two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $7.00.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares in the company, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 8.43% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $4.77 on Thursday. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a 50-day moving average of $5.47 and a two-hundred day moving average of $5.80. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -2.68 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. During the same quarter in the previous year, the business earned ($0.40) earnings per share. The business's quarterly revenue was up 33.3% compared to the same quarter last year. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.